(14) in 2015 who revealed that compared to ipilimumab, Nivolumab alone or in combination with ipilimumab in patients with previously untreated metastatic melanoma significantly improved progression-free survival by enabling complementary activity between PD-1 and CTLA-4 blockade. Here, CTLA4 is linked to metastatic melanoma.